1. Home
  2. CBIO vs TRVG Comparison

CBIO vs TRVG Comparison

Compare CBIO & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc. Common Stock

HOLD

Current Price

$13.17

Market Cap

252.6M

Sector

N/A

ML Signal

HOLD

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$2.92

Market Cap

278.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
TRVG
Founded
2003
2005
Country
United States
Germany
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
252.6M
278.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
TRVG
Price
$13.17
$2.92
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$25.60
$3.96
AVG Volume (30 Days)
181.7K
60.6K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$614,486,683.00
Revenue This Year
N/A
$18.36
Revenue Next Year
N/A
$9.18
P/E Ratio
N/A
$101.49
Revenue Growth
N/A
14.41
52 Week Low
$9.81
$2.02
52 Week High
$21.40
$5.83

Technical Indicators

Market Signals
Indicator
CBIO
TRVG
Relative Strength Index (RSI) 48.69 45.89
Support Level $12.27 $2.71
Resistance Level $16.35 $3.18
Average True Range (ATR) 1.08 0.11
MACD -0.12 0.02
Stochastic Oscillator 21.44 50.00

Price Performance

Historical Comparison
CBIO
TRVG

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.

Share on Social Networks: